As if Big Pharma always gets it right, and never overpays either ... see CELG and Juno and maybe CELG for GED-301 and maybe even Ozanimod. Jury out on both, esp the former.
And then there's Pfizer and Medivation. See below.
Brilacidin truly could be the Best Buy, hands down, ever, in the annals of Biotech. DeGrado and Klein (Natl Academy of Science inductees) and the other members of the PYMX braintrust designed a phenomenal drug that only improved on what the Body already is expert at... Host Defense.
Whichever Ehrlich son clued dad in on the opportunity, as rumor has it, deserves huge kudos, and a nice inheritance.
Brilacidin is a Platform (pipeline in a) drug that should just keep on giving... the other HDP-Ms could also make it to market.
I don't understand the mentality that if only management were out of the way the science could prevail. B was purchased off the trash heap. Nobody wanted it. A flailing OTC Pink Sheet stock picked it up and sent PR's to Obama to pump the stock up and secure financing to keep the lights on for a few years.
K did have a chance at one point. The odds of it having an impact have diminished to near zero.
Luckily for Menon, he probably found a way to capitalize on K through Aruda. Pretty genius way to do it and the shareholders never asked for a detailed reason that the Aruda settlement came out of nowhere.
Market Data 
Markets 
AI
